According to the Financial Times top executives at Société Générale ordered the bank’s manipulation of the US-dollar Libor interest rate sin 2015.
Michel Péretié, the former head of corporate and investment banking, and Didier Valet, who recently resigned as deputy chief executive, allegedly directed the rate-rigging scheme, according to a Department of Justice letter to the French authorities.
The DoJ wrote that evidence it had gathered, including from documents produced by SocGen and its lawyers, “indicates that the directives to submit these falsely low rates came from” Mr Péretié, Mr Valet and two lower-level employees, reported FT.
The company on Monday agreed a $1.3bn settlement with US and French authorities over the Libor rate-rigging and a separate Libyan bribery case. Between 2004 and 2009, the French bank paid $90 million in bribes to a Libyan broker, who then paid Libyan officials, the US Justice Department announced. In addition to a $585 million fine for the foreign bribery case, Société Générale will pay $275 million for manipulating the London InterBank Offered Rate between May 2010 and October 2011.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas